Richard Paxman, CEO at Paxman

“Like my mum, many people find hair loss to be extremely traumatic. It is estimated that 8% of patients actually refuse chemotherapy because they do not want to lose their hair. After experiencing this first hand, we have been determined to change this, and help minimize hair loss in women who are undergoing chemotherapy for breast cancer, positively contributing to their overall health and recovery.”

As part of the FDA clearance process, the Paxman scalp cooler was used in the first-ever randomized clinical trial to evaluate modern scalp cooling, which took place at several sites including Baylor College of Medicine, Memorial Sloan Kettering, the U.S. Oncology Network, Cleveland Clinic & Summit Medical Group - MD Anderson Cancer Center.

The multi-center prospective study, which involved 186 women across New Jersey, New York, Texas, and Ohio, revealed that the cold cap preserved hair in more than 50% of the women who used it.

Speaking about results lead researcher Dr. Julie Nangia, MD, Assistant Professor of Medicine at Baylor College of Medicine, Houston, Texas, USA added: “The Paxman Hair Loss Prevention System is a safe and effective method for reducing hair loss in women being treated with chemotherapy for breast cancer, especially for those on taxane-based regimens.”

“Hopefully five years from now, we will consider scalp cooling part of routine practice, the same way that we can see an IV-pump with an IV-pole as part of the regular equipment you would expect in an infusion suite. It’s important that people undergoing chemotherapy understand what scalp cooling is and that it is an option available to them if they want to prevent hair loss.”

Over the next 12 months, Paxman plans to install 250 systems across the U.S. and will be working with a large number of cancer centers and large community oncology groups to roll out their scalp cooling systems.

The Company aims to revolutionize the current landscape of scalp cooling by ensuring that affordability is at the center of the treatment giving more patient choices.

This involves launching a single patient use personal cap model, which will be loaded with scalp cooling credits depending on the number of chemotherapy infusions they are having.

Patients using scalp cooling treatment will only pay for their own cap and the treatment they use.

Richard added: “The USA is the largest healthcare market in the world with over 1.6 million diagnoses of cancer each year. We have spent six years conducting a comprehensive multi-center randomized clinical trial to ensure our data is as robust as possible. This has been a significant investment for us, but we are incredibly excited to be able to offer scalp cooling to US patients giving them a choice to maintain some control during treatment as we see in the UK and other parts of the world.”